The fight against colon cancer got an infusion of funds Wednesday as the Ontario government and leading medical research centres joined with the world's largest pharmaceutical research company to develop new drugs.
Pfizer, a New York-based company with 1,400 employees across Canada, is partnering with the Ontario Cancer Institute and the Ontario Institute for Cancer Research in a $6.9-million collaboration over three years.See also: Pfizer Gives $5.4M for Ontario Cancer Research Project, GenomeWeb Daily News, July 16, 2009. [Free registration required][Twitter entry]. Excerpts:
Pfizer Global Research and Development will collaborate with two Ontario institutes to discover and validate targets that could be used to diagnose, predict, or treat colorectal cancer.
Ben Neel, who is director of OCI and is serving as a principal investigator on the project, said in a statement that the collaboration will "join the world class genomics and informatics programs at OICR, cutting edge research in cancer stem cell biology and functional genomics at OCI/PMH and the world's largest pharmaceutical company in a concerted effort to bring new therapies to colon cancer patients worldwide."